Add to ORKGIntroduction: New therapies with genes, tissues and cells have taken the emerging field for the treatment of many diseases. Advances on stem cell therapy research have led to international regulatory agencies to harmonize and regulate the development of new medicines with stem cells
Many actors influence the framing of EU legislation and regulation applicable to gene and cell thera...
Regenerative medicine is a new and promising mode of therapy for patients who have limited or no oth...
International audienceIn the European Union, gene and cell therapy medicinal products are mainly reg...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
In the last 20 years, the global regulatory frameworks for drug assessment have been managing the ch...
In the last decade, many clinical trials with gene- and cell-based therapies were performed and incr...
Gene and cell-based therapies (GCTs) have the potential to revolutionize healthcare. Recently, genet...
Therapies based on genetically modified cells hold great promise for the treatment of various diseas...
The use of stem cells as medicines is a promising and upcoming area of research as they may be able ...
1.BackgroundCommunicating information on the regulatory framework applicable to gene and cell therap...
Mesenchymal stromal/stem cells (MSCs) are used to treat a wide variety of diseases. The conditions f...
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The Eu...
The evolving regulatory landscape for clinical stem cell research is characterized by a conflict bet...
Advances in stem cell biology and immunology raise hopes for new developments in regenerative medici...
Many actors influence the framing of EU legislation and regulation applicable to gene and cell thera...
Regenerative medicine is a new and promising mode of therapy for patients who have limited or no oth...
International audienceIn the European Union, gene and cell therapy medicinal products are mainly reg...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
In the last 20 years, the global regulatory frameworks for drug assessment have been managing the ch...
In the last decade, many clinical trials with gene- and cell-based therapies were performed and incr...
Gene and cell-based therapies (GCTs) have the potential to revolutionize healthcare. Recently, genet...
Therapies based on genetically modified cells hold great promise for the treatment of various diseas...
The use of stem cells as medicines is a promising and upcoming area of research as they may be able ...
1.BackgroundCommunicating information on the regulatory framework applicable to gene and cell therap...
Mesenchymal stromal/stem cells (MSCs) are used to treat a wide variety of diseases. The conditions f...
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The Eu...
The evolving regulatory landscape for clinical stem cell research is characterized by a conflict bet...
Advances in stem cell biology and immunology raise hopes for new developments in regenerative medici...
Many actors influence the framing of EU legislation and regulation applicable to gene and cell thera...
Regenerative medicine is a new and promising mode of therapy for patients who have limited or no oth...
International audienceIn the European Union, gene and cell therapy medicinal products are mainly reg...